Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Deffered Revenue: 2021-2022

Historic Non-Current Deffered Revenue for Spyre Therapeutics (SYRE) over the last 2 years, with Dec 2022 value amounting to $2.2 million.

  • Spyre Therapeutics' Non-Current Deffered Revenue fell 1.31% to $2.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.3 million, marking a year-over-year decrease of 1.31%. This contributed to the annual value of $2.2 million for FY2022, which is 79.05% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Non-Current Deffered Revenue of $2.2 million as of FY2022, which was up 79.05% from $1.2 million recorded in FY2021.
  • Spyre Therapeutics' 5-year Non-Current Deffered Revenue high stood at $2.2 million for FY2022, and its period low was $1.2 million during FY2021.
  • Its 2-year average for Non-Current Deffered Revenue is $1.7 million, with a median of $1.7 million in 2021.
  • Data for Spyre Therapeutics' Non-Current Deffered Revenue shows a peak YoY spiked of 79.05% (in 2022) over the last 5 years.
  • Over the past 2 years, Spyre Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $1.2 million in 2021, then surged by 79.05% to $2.2 million in 2022.